The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

J&J announced the FDA’s supplemental approval Tuesday. Previously, Spravato was approved as an add-on therapy for treatment-resistant depression, in conjunction with an oral antidepressant.

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

The US Food and Drug Administration’s (FDA’s) decision makes Spravato the first-ever standalone treatment for adults with treatment-resistant depression. Initially approved in 2019 for use ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant depression. This marks a significant advancement in depression treatment ...